Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. | Ionis ...

The National Triglyceride Alliance (NTA) is proud to announce its official launch, marking a pivotal step in advancing ...

Investment analysts at StockNews.com began coverage on shares of Amarin (NASDAQ:AMRN – Get Free Report) in a research note issued on Sunday. The firm set a “sell” rating on the biopharmaceutical ...

Activist investor Sarissa Capital won control over Amarin’s board two years ago on a fierce campaign of stirring up value for ...

Amarin Corp. (AMRN) gains 6.3% as major shareholders push for a strategic review to recover value after a dramatic stock drop ...

Bradley Radoff and Michael Torok, the Managing Director of JEC Capital Partners, who collectively own approximately 15M shares of Amarin ...

While we appreciate Sarissa Capital Management's ("Sarissa") involvement and commitment to the Company, we believe shareholders would be best served by the Board immediately conducting a strategic ...

Corporation announced that additional in vitro mechanistic data with eicosapentaenoic acid, EPA, will be presented at the ...

Japan’s Kadokawa is set to make a splash at this year’s Hong Kong FilMart with two new titles aimed at the Asian market, both ...

Amarin Corporation plc (NASDAQ:AMRN) Q4 2024 Earnings Call Transcript March 12, 2025 Amarin Corporation plc beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.06.

Amarin Corp PLC (AMRN) reports strong international growth and strategic advancements despite US market pressures.